Search Results - "Hitier, S."

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study by Van Cutsem, E., Boni, C., Tabernero, J., Massuti, B., Middleton, G., Dane, F., Reichardt, P., Pimentel, F.L., Cohn, A., Follana, P., Clemens, M., Zaniboni, A., Moiseyenko, V., Harrison, M., Richards, D.A., Prenen, H., Pernot, S., Ecstein-Fraisse, E., Hitier, S., Rougier, P.

“…Docetaxel/cisplatin/infusional 5-fluorouracil (5-FU; DCF) is a standard chemotherapy regimen for patients with advanced gastric cancer (GC). This phase II…”
Get full text

RELATION BETWEEN BENIGN GYNECOLOGICAL DISEASES AND INCIDENT HYPERTENSION IN THE E3N COHORT by Bonnet, F, Hitier, S, Gelot, A, Fagherazzi, G, Boutron-Ruault, M.C

“…OBJECTIVE:It has been reported that women with uterine fibroids are more often overweight and hypertensive but the prospective relationship between benign…”
Get full text

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial by Mackey, J.R., Pieńkowski, T., Crown, J., Sadeghi, S., Martin, M., Chan, A., Saleh, M., Sehdev, S., Provencher, L., Semiglazov, V., Press, M.F., Sauter, G., Lindsay, M., Houé, V., Buyse, M., Drevot, P., Hitier, S., Bensfia, S., Eiermann, W.

“…The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared sequential to concurrent combination of doxorubicin and cyclophosphamide…”
Get full text

Post hoc analysis of the effect of baseline characteristics on treatment duration in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the compassionate use (CUP)/expanded access programs (EAP) and CAPRISTANA registry by Malik, Z., Pichler, A., Di Lorenzo, G., De Giorgi, U., Hitier, S., Ecstein-Fraisse, E., Ozatilgan, A., Carles, J.

Get full text

2549 Treatment patterns in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC) previously treated with docetaxel (DOC)-based chemotherapy (CT): PROXIMA 1-year analysis by Akaza, H, Procopio, G, Pripatnanont, C, Facchini, G, Fava, S, Wheatley, D, Leung, K.C, Butt, M, Silva, A, Castillo, L, Karavasilis, V, Hitier, S, Ecstein-Fraisse, E.B, Bensfia, S, roglu, M. Ö zgü

Get full text

818PPost hoc analysis of the effect of baseline characteristics on treatment duration in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the compassionate use (CUP)/expanded access programs (EAP) and CAPRISTANA registry by Malik, Z, Pichler, A, Di Lorenzo, G, De Giorgi, U, Hitier, S, Ecstein-Fraisse, E, Ozatilgan, A, Carles, J

Get full text

The effect of island size and isolation on old growth forest habitat and bird diversity in Gwaii Haanas (Queen Charlotte Islands, Canada) by Martin, J.-L, Gaston, A.J, Hitier, S

“…We surveyed the vegetation and bird faunas of forests on 65 islands in the Gwaii Haanas archipelago of British Columbia, Canada, ranging in size from 1 to >…”
Get full text

Prévalence de l’hyperparathyroidie primaire associée à un syndrome de Turner à l’âge adulte by Suteau, V., Hitier, S., Illouz, F., Rodien, P., Briet, C.

“…Le syndrome de Turner présente de multiples comorbidités dont l’ostéoporose. L’hyperparathyroïdie primaire peut être associée à une ostéoporose. Quelques cas…”
Get full text

Health-related quality of life (HRQL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) in a prospective observational study (CAPRISTANA) by Pichler, A., Barnes, G., Katolicka, J., Korunkova, H., Tomova, A., Ghosn, M., El Karak, F., Koroleva, I., Makdessi, J., Ozatilgan, A., Hitier, S., Carles, J.

Get full text

CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent by de Wit, R., Fizazi, K., Efstathiou, E., Dittamore, R., Hitier, S., Pantel, K., Sternberg, C., Tombal, B., Wülfing, C., de Bono, J.

Get full text

106 Cabazitaxel adverse events are manageable in senior adults with metastatic castration-resistant prostate cancer (mCRPC): Results of the European Compassionate Use Programme by Heidenreich, A, Bracarda, S, Mason, M, Ozen, H, Sengelov, L, Gerritsen, W, Papandreou, C, Fossa, S, Hitier, S, Climent, M

Get full text

Safety of Cabazitaxel + Prednisone (Cbz + P) in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Previously Treated with Docetaxel (Doc): Cohort Compassionate-Use Programme (Cup) by Heidenreich, A., Scholz, H., Ozen, H., Pripatnanont, C., van Oort, I.M., Gerritsen, W.R., Efstathiou, E., Rinck, J.A., Lee, J., Boumessous, A., Su, Z., Hitier, S., Ardavanis, A.

Get full text

782PSAFETY OF CABAZITAXEL + PREDNISONE (CBZ + P) IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL (DOC): COHORT COMPASSIONATE-USE PROGRAMME (CUP) by Heidenreich, A., Scholz, H., Ozen, H., Pripatnanont, C., van Oort, I.M., Gerritsen, W.R., Efstathiou, E., Rinck, J.A., Lee, J., Boumessous, A., Su, Z., Hitier, S., Ardavanis, A.

“…Abstract Aim: In the Phase III TROPIC trial, Cbz + P improved survival vs. mitoxantrone + P in pts with mCRPC previously treated with DOC (P < 0.0001). A CUP…”
Get full text

Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer by Slamon, DJ, Eiermann, W, Robert, NJ, Giermek, J, Martin, M, Jasiowka, M, Mackey, JR, Chan, A, Liu, M-C, Pinter, T, Valero, V, Falkson, C, Fornander, T, Shiftan, TA, Bensfia, S, Hitier, S, Xu, N, Bée-Munteanu, V, Drevot, P, Press, MF, Crown, J

“…Abstract Background: BCIRG-006 was study designed to assess the relative efficacy and safety of two trastuzumab-based regimens compared to a standard…”
Get full text

Tolerability of Cabazitaxel in Senior Adults with Metastatic Castration-Resistant Prostate Cancer (MCRPC) in Europe by Heidenreich, A., Bracarda, S., Mason, M., Ozen, H., Sengelov, L., Gerritsen, W., Papandreou, C., Fossa, S., Hitier, S., Climent, M.

Get full text

792PTREATMENT PATTERNS IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL (DOC)-BASED CHEMOTHERAPY (CTX): PROXIMA by Akaza, H., Procopio, G., Pripatnanont, C., Facchini, G., Fava, S., Wheatley, D., Leung, K.C., Butt, M., Silva, A., Castillo, L., Fountzilas, G., Hitier, S., Ecstein-Fraisse, E.B., Bensfia, S., Özgüroğlu, M.

“…Abstract Aim: PROXIMA is a prospective, international registry study of treatment patterns over 12 months and survival at 24 months in pts with mCRPC during or…”
Get full text

Treatment Patterns in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Previously Treated with Docetaxel (Doc)-Based Chemotherapy (Ctx): Proxima by Akaza, H., Procopio, G., Pripatnanont, C., Facchini, G., Fava, S., Wheatley, D., Leung, K.C., Butt, M., Silva, A., Castillo, L., Fountzilas, G., Hitier, S., Ecstein-Fraisse, E.B., Bensfia, S., Özgüroğlu, M.

Get full text

Cabazitaxel (CBZ) + Prednisone (P; CBZP) in Patients (PTS) with Metastatic Castration-Resistant Prostate Cancer (MCRPC) Previously Treated with Docetaxel (D): Interim Results from Compassionate-Use Programme (CUP) and Early-Access Programme (EAP) by Malik, Z.I., Di Lorenzo, G., Basaran, M., Parente, P., de Schultz, W., Gerritsen, W.R., Aparicio, L.M. Anton, Hitier, S., Heidenreich, A., Bahl, A.

Get full text

On the Efficiency of Interim Analyses Applied to Nonclinical Studies by Maïofiss-Dullin, L., Boussac-Marlière, N., Geffray, B., Haimez, C., Harriong, S., Hitier, S., Onado, V.

“…Interim analyses, commonly applied in clinical trials, are rarely used in the nonclinical field, although they are potentially useful for ethical and practical…”
Get full text

Analysis of the inflammatory response induced by rhMMP-12 catalytic domain instilled in mouse airways by Nénan, Soazig, Planquois, Jean-Michel, Berna, Patrick, De Mendez, Isabelle, Hitier, Simon, Shapiro, Steve D., Boichot, Elisabeth, Lagente, Vincent, Bertrand, Claude P.

“…Macrophage elastase (MMP-12) is a metalloproteinase able to degrade extracellular matrix components such as elastin. As many MMPs, MMP-12 is involved in acute…”
Get full text